A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulation Protein, NESP) and rHuEPO for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy

Inclusion Criteria:

- Men or women of legal age, diagnosed with a non-myeloid malignancy and scheduled to
receive at least 12 additional weeks of cyclic cytotoxic chemotherapy from the time
of first dose of study drug

- Screening hemoglobin concentration less than or equal to 11.0 g/dL

- ECOG performance status of 0 to 2 (inclusive)

Exclusion Criteria:

- History of seizure disorder

- Primary hematologic disorder that could cause anemia

- Unstable or uncontrolled disease/condition related to or affecting cardiac function

- Clinical evidence of chronic infection/inflammatory disease

- Positive test for HIV infection

- Previously confirmed neutralizing antibodies to rHuEPO

- Received rHuEPO or darbepoetin alfa therapy within 4 weeks of study day 1 or more
than 2 RBC transfusion occurences